SY1365 phase 1 clinical trial for CDK 7 mutation

The liver mets from my breast cancer have a CDK7 mutation, which apparently is rare as compared to mutations of CDK 4 or 6 (treated with Ibrance and Fulvestrant).

I’ve just finished two cycles (three months) of SY1365 made by Syros Pharmaceuticals as part of a phase 1 trial, now awaiting the results of CT scan and liver biopsy to determine if this drug has made any impact.  It certainly has made me sick along the way with innumerable GI side effects which are only worth enduring if there is a benefit.

I’m not sure whether there are any other chemo options specific to the CDK7 mutation; if anyone else out there has, I’d love to hear from you.